Ebastine - review of the efficacy and safety profile of a nonsedating antihistamine

Ebastine represents a modem nonsedating antihistamine with favorable pharmacological and clinical properties. It is licensed in the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. The pharmacologically active metabolite carebastine reaches C-max at 4 h, demonstrates plasma elimination half-life values of 15 - 19 h and is mainly eliminated renally. Clinical studies did not demonstrate relevant anticholinergic or cardial side effects. In contrast, the substance has several anti-inflammatory effects and a high antihistaminic activity which are responsible for its potency. In comparison to loratadine and cetirizine, the efficacy of ebastine 10 mg is equally potent or better. Moreover, the licensed 20 mg dose has additional clinical effects in the treatment of allergic rhinitis. Ebastine demonstrates an advantageous risk-benefit profile and thus is another important option in the treatment of immediate allergic reactions.